Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agave fructans, specifically agavins, are complex, highly branched neo-fructans derived from the *Agave* genus, particularly *Agave tequilana* Weber var. azul. Unlike the linear β(2-1) linkages found in chicory-derived inulin, agavins contain both β(2-1) and β(2-6) linkages, resulting in a unique architecture that resists enzymatic digestion in the upper gastrointestinal tract. Functioning as prebiotics, they are fermented by the colonic microbiota, leading to the production of short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. This process is associated with the modulation of gut hormones (e.g., GLP-1 and PYY) that regulate satiety and glucose homeostasis. Clinical evidence suggests that agave fructans can significantly reduce body mass index (BMI), total body fat, and serum triglycerides in obese individuals, making them a promising nutraceutical intervention for metabolic syndrome and weight management.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on agave fructans.